Introduction
The elimination of staphylococci, particularly methicillin-resistant Staphylococcus aureus (MRSA), from the nose plays a crucial role in infection control protocols. Currently, one of the most effective topical agents for eradication of nasal carriage of MRSA is mupirocin. 1 This antimicrobial agent is also used to prevent catheter colonization by coagulase-negative staphylococci (CoNS). However, staphylococcal isolates resistant to mupirocin are found worldwide. 2, 3 Staphylococci expressing mupirocin resistance can be divided in two groups: low-level resistant (MuL) with MICs in the range 8-256 mg/L and high-level resistant (MuH) with MICs ≥ 512 mg/L. Low-level resistance to mupirocin is more common and is thought to arise from point mutations within the usual chromosomal staphylococcal isoleucyl-tRNA synthetase gene (ileS). 1 High-level resistance results from acquisition of a transferable plasmid carrying a new gene, ileS-2, encoding a second novel staphylococcal isoleucyl-tRNA synthetase, which has no affinity to mupirocin. 1 Low and high-level resistance has been detected in both S. aureus and CoNS.
In Greece, mupirocin is only used to eradicate nasal carriage of MRSA in patients and staff. The antibiotic is not used for the treatment of staphylococcal skin infections or for the prevention of bacterial colonization due to coagulase-negative staphylococci. In the present study, we investigated the rate of development of mupirocinresistant staphylococci (S. aureus and CoNS) in Greek hospitals during 1999-2002. 
Materials and methods

Bacterial isolates
Susceptibility tests
All isolates were tested using the mupirocin Etest (AB BIODISK, Solna, Sweden), and interpretation of susceptibility test results was conducted following the recommendations of the mupirocin manufacturer. Susceptibility results obtained by Etest were compared with those obtained after MIC determination using the reference agar dilution method. 4 Potential coresistance to 14 antimicrobial agents (ampicillin, oxacillin, trimethoprim/ sulfamethoxazole, ofloxacin, clindamycin, erythromycin, gentamicin, tobramycin, rifampicin, tetracycline, fusidic acid, vancomycin, linezolid and quinupristin/dalfopristin) was also determined by the agar diffusion method. 5
Detection of ileS-2 and mecA genes
All isolates were tested for the presence of ileS-2 and mecA genes by PCR, as described previously. 6 The predicted size of the PCR products were 456 bp and 310 bp for the ileS-2 and mecA fragments, respectively.
PFGE analysis
Molecular typing of the mupirocin-resistant isolates was performed by PFGE analysis. 7, 8 The banding patterns of the strains were compared visually following the criteria of Tenover et al. 7
Results
A total of 556 staphylococci were found to be mupirocin-resistant by both agar dilution and Etest (MIC ≥ 8 mg/L). No discrepancies were observed between the reference agar dilution and Etest MIC values. The MuL staphylococcal strains with mupirocin MICs in the range 8-256 mg/L were easily recognized by the Etest, having a faint but visible zone of inhibition around the Etest strips. The MuH staphylococcal strains with mupirocin MICs ≥ 512 mg/L all had heavy, confluent growth with no detectable zones around the Etest strips. Among the 1200 S. aureus isolates, 24 (2%) expressed mupirocin resistance during the study period. These 24 isolates were collected from patients; none of them had taken mupirocin treatment for nasal carriage. The distribution of low-and high-level mupirocin resistance in relation to time of isolation is described in Table 1 . The rate of mupirocin resistance among S. aureus isolates was low and has remained steady since 1999. MuL was detected only in four mecApositive S. aureus isolates (MIC 32 mg/L), belonging to clones A (three) and B (one), which have spread in several Greek hospitals. 8 MuH (MIC ≥ 512 mg/L) was detected in 20 S. aureus isolates (14 mecA-positive), sporadically isolated in two of the four participating hospitals. PFGE analysis revealed that all of the MuH strains belonged to clone A, which expressed a relatively susceptible phenotype ( (Table 2) .
As expected, all MuH isolates carried the ileS-2 gene, which was not detected in any MuL isolate. Analysis by PFGE showed that, although MuH S. epidermidis strains fell into six distinct clones (i, d, b, g, l, c), the great majority of isolates, 286 out 436 (65.6%), belonged to clone i (Figure 1) . 9 Before 1999, strains belonging to this clone did not carry the ileS-2 gene, so the resistant mutants have emerged in the last 4 years (data not shown). The MuL S. epidermidis strains were grouped into six different clones (a, e, i, d, c, b) , the most dominant being clone a, comprising 64 out of 92 strains (69.56%). 
Discussion
During the last decade, the increasing number of methicillin-resistant S. aureus worldwide has resulted in greater use of topical application mupirocin to prevent colonization and subsequent infection. However, the use of mupirocin, especially after prolonged duration of topical treatment and/or in areas of highly concentrated drug, such as skin infections and burns, leads to the emergence of resistance. Mupirocin resistance is relatively unusual in S. aureus, but it is common and increasing in CoNS. It varies greatly from institution to institution regardless of geographic region monitored. According to the SENTRY antimicrobial surveillance programme 2000, mupirocin resistance rates from bloodstream infections varied by geographic area (USA, Canada, Latin America and Europe) for S. aureus from 1.9% to 5.6% and for CoNS from 12.8% to 39.9%. 2 A previous study in 19 European hospitals in 12 countries reported high-level resistance in 1.6% of S. aureus and 5.6% of CoNS isolates, and lowlevel resistance in 2.3% of S. aureus and 7.2% of CoNS isolates. 3 The prevalence of mupirocin-resistant S. aureus in Greek hospitals in this study is lower than that reported in a previous study (1.8% in 2002 versus 4.5% in 1997). 10 However, the rate of mupirocin-resistant CoNS has increased dramatically, ranging from 9% in 1999 to 33% in 2002. The predominance of the clones A (among MuH S. aureus, which has spread in several Greek hospitals), 8 and i and a (among MuH and MuL S. epidermidis strains), already characterized as epidemic clones, 9 suggests that a limited number of mupirocin-resistant clones has been disseminated in the Greek hospital environment. This is not surprising for chromosomally mediated MuL, but is less expected for plasmid-mediated MuH, where horizontal spread of the plasmid among genetically diverse strains is likely. The high prevalence of mupirocin-resistant staphylococci was due mainly to clonal dissemination and to a lesser extent to gene spread.
The resistance profiles of the isolates have shown that the overwhelming majority of these were resistant to methicillin. Linezolid, quinupristin/dalfopristin and vancomycin maintained high activity against essentially all mupirocin-resistant strains.
In the period 1999-2002 in Greece, a rising incidence of mupirocinresistant CoNS has been observed. In contrast, mupirocin resistance in S. aureus has remained more constant. In our hospitals, the use of mupirocin is limited and it is only used for controlling the spread of MRSA. The low-rate of mupirocin-resistant S. aureus is due to the limited MRSA exposure to mupirocin and any subsequent development of resistance. On the other hand, the finding that mupirocin resistance is more common among S. epidermidis than S. aureus could be explained by the capacity of certain clones (i, a) to spread widely. Thus, the increased rate of mupirocin-resistant CoNS in Greece is related to the spread of methicillin-resistant epidemic hospital clones rather than the consumption of mupirocin. Measures to combat this spread, such as effective control of hospital clones, would appear to be prudent.
